Medeor Therapeutics, Inc., a San Mateo, CA-based clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies, closed a $57m Series B financing.
The round was led by RA Capital Management with participation from Sofinnova Ventures and 6 Dimensions Capital, and existing investors Vivo Capital and WuXi Healthcare Ventures. In conjunction with the financing, Peter Kolchinsky, Ph.D., Portfolio Manager and Managing Director at RA Capital, and Anand Mehra, M.D., General Partner at Sofinnova Ventures, joined Medeor’s Board of Directors.
The company intends to use the funds to conduct the Phase 3 clinical trial of MDR-101 in living donor HLA-matched kidney transplant patients, under a Special Protocol Agreement with the FDA, as well as a Phase 2b trial of MDR-102 in living donor HLA-mismatched kidney transplant patients, and initiate development of MDR-103 for the induction of delayed immune tolerance and MDR-104 to address the needs of deceased donor kidney transplant patients.
Led by Steven R. Deitcher, M.D., Co-founder, President and CEO, Medeor Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients. Its series of product candidates each comprise a unique composition of different types of hematopoietic organ donor-derived cells, based on technologies discovered at Stanford University and exclusively licensed by Medeor. These product candidates are designed to produce mixed chimerism, the co-existence of both recipient and donor blood and immune cells in the recipient, to achieve donor-specific immune tolerance, to prevent transplant organ loss, to reduce or eliminate chronic immunosuppressive drug therapy, and thereby to improve patient outcomes.